Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions

Drug Discov Today. 2016 Jan;21(1):180-189. doi: 10.1016/j.drudis.2015.10.012. Epub 2015 Oct 23.


Antibody-cytokine fusion proteins, often referred to as immunocytokines, represent a novel class of biopharmaceutical agents that combine the disease-homing activity of certain antibodies with the immunomodulatory properties of cytokine payloads. Originally, immunocytokines were mainly developed for cancer therapy applications. More recently, however, the use of anti-inflammatory cytokines for the treatment of chronic inflammatory conditions and to treat autoimmune diseases has been considered. This review analyzes basic principles in the design of immunocytokines and describes the most advanced products in preclinical and clinical development.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / immunology
  • Cytokines / immunology
  • Cytokines / pharmacology*
  • Cytokines / therapeutic use*
  • Humans
  • Inflammation / drug therapy*
  • Inflammation / immunology


  • Antibodies, Monoclonal
  • Cytokines